We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+13.27%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.42B
AUM Growth
-$150M
Cap. Flow
-$442M
Cap. Flow %
-12.92%
Top 10 Hldgs %
65.01%
Holding
63
New
3
Increased
6
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
FDMT icon
4D Molecular Therapeutics
FDMT
+$57.4M
2
XNCR icon
Xencor
XNCR
+$16M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.97M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$9.39M
5
AXSM icon
Axsome Therapeutics
AXSM
+$7.94M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$109M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$80.7M
3
MRUS
Merus
MRUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$59.4M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.57B
$1.1B 32.08%
21,751,284
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.51B
$244M 7.15%
5,161,801
– –
RVMD icon
3
Revolution Medicines
RVMD
$39.9B
$158M 4.62%
3,478,612
-2,502,600
-42% -$109M
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.46B
$120M 3.51%
3,075,907
-1,294,117
-30% -$51.6M
TYRA icon
5
Tyra Biosciences
TYRA
$1.9B
$110M 3.21%
4,661,194
– –
OLMA icon
6
Olema Pharmaceuticals
OLMA
$1B
$109M 3.19%
9,135,893
– –
GPCR icon
7
Structure Therapeutics
GPCR
$3.41B
$98.3M 2.87%
2,238,986
-248,776
-10% -$9.62M
CGEM icon
8
Cullinan Oncology
CGEM
$1.01B
$96.3M 2.82%
5,750,683
– –
XOMA
9
DELISTED
Xoma
XOMA
$96.2M 2.81%
3,633,743
– –
AXSM icon
10
Axsome Therapeutics
AXSM
$11.2B
$94M 2.75%
1,046,000
+91,000
+10% +$7.94M
PTGX icon
11
Protagonist Therapeutics
PTGX
$8.79B
$83.3M 2.44%
1,850,167
-1,469,123
-44% -$59.4M
FDMT icon
12
4D Molecular Therapeutics
FDMT
$532M
$79.8M 2.33%
7,382,642
+3,460,229
+88% +$57.4M
ACIU icon
13
AC Immune
ACIU
$223M
$73.8M 2.16%
19,522,436
+687,500
+4% +$2.4M
GHRS icon
14
GH Research
GHRS
$1.93B
$69.6M 2.04%
10,400,158
– –
KURA icon
15
Kura Oncology
KURA
$800M
$65.9M 1.93%
3,371,761
-710,276
-17% -$14.4M
THRD
16
DELISTED
Third Harmonic Bio
THRD
$59.2M 1.73%
4,365,933
– –
IONS icon
17
Ionis Pharmaceuticals
IONS
$8.6B
$58.2M 1.7%
1,451,879
-1,734,497
-54% -$80.7M
ZYME icon
18
Zymeworks
ZYME
$1.61B
$57.8M 1.69%
4,607,935
-1,262,065
-22% -$13.7M
EPIX
19
DELISTED
ESSA Pharma
EPIX
$53M 1.55%
8,748,629
– –
AGIO icon
20
Agios Pharmaceuticals
AGIO
$1.79B
$52.9M 1.55%
1,190,107
– –
CELC icon
21
Celcuity
CELC
$4.21B
$51.7M 1.51%
3,466,000
– –
ETNB
22
DELISTED
89bio
ETNB
$50.4M 1.47%
6,811,631
-756,848
-10% -$6.36M
FHTX icon
23
Foghorn Therapeutics
FHTX
$266M
$49.4M 1.44%
5,302,000
– –
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$45.2M 1.32%
1,569,422
– –
IDYA icon
25
IDEAYA Biosciences
IDYA
$3.42B
$44.7M 1.31%
1,409,993
+247,687
+21% +$9.39M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2024 Portfolio in Review

As of Q3 2024, BVF Inc held 63 positions worth $3.42B, down 4.2% from $3.57B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

BVF Inc withdrew a net $442M in Q3 2024, closing 8 positions and reducing 10 holdings. Its most notable exit was Merus, an estimated $75.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Xencor worth $17.1M.

  • BVF Inc's largest Q3 2024 buy was Xencor: 850,000 shares worth $17.1M.
  • BVF Inc added most to 4D Molecular Therapeutics in Q3 2024, an estimated $57.4M increase.
  • BVF Inc's biggest Q3 2024 reduction was Revolution Medicines, cutting an estimated $109M.
  • BVF Inc fully exited Merus in Q3 2024, selling an estimated $75.7M.
  • BVF Inc's ten largest holdings make up 65% of its $3.42B portfolio in Q3 2024.
  • BVF Inc opened 3 new positions and closed 8 in Q3 2024.
  • BVF Inc's portfolio value fell 4.2% quarter-over-quarter to $3.42B.

Based on BVF Inc's 13F filing for Q3 2024, filed 14 Nov 2024.